Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Definite AS (arthritis of the spine) as defined by the modified New York criteria, for at least 3 months prior to first dose of study drug~* Symptoms of active disease at screening and at baseline visits, as evidenced by both a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of \>= 4, and a Total Back Pain score of \>= 4 (each on a scale of 0 to 10cm)~* Inadequate response to 3 months of continuous therapy with maximal recommended doses of NSAIDs, or else unable to receive a full 3 months of maximal NSAID therapy because of intolerance, toxicity, or contraindications to non-steroidal anti-inflammatory drugs (NSAIDs)~* Stable doses of methotrexate, sulfasalazine, hydroxychloroquine, low-dose corticosteroids, and NSAIDs are permitted.~Exclusion Criteria:~* Patients cannot have complete ankylosis of the spine~* No prior treatment with biologic anti-TNF agents (infliximab, etanercept, adalimumab)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 003 (Type: EXPERIMENTAL): golimumab 100 mg sc injections every 4 wks from wk 0 up to 5 yrs
- 001 (Type: PLACEBO_COMPARATOR): Golimumab (CNTO 148); placebo SC injections every 4 wks thru wk 20 (unless early escape at wk 16);golimumab - if early escape, 50mg sc inj every 4wks from wk 16 up to 5yrs ;golimumab -50mg sc injection beginning wk 24 up to 5 yrs (unless early escape); golimumab- Dr's discretion after unblinding, dose adjust from 50 to 100mg
- 002 (Type: EXPERIMENTAL): golimumab 50 mg sc injs every 4wks from wk 0 thru 5yrs (unless early escape at wk 16); golimumab - If early escape, 100mg sc injections every 4 wks beginning wk 16 up to 5 yrs ; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg

Based on this trial design, predict the completion outcome and termination type (if applicable).